{
    "root": "346893b1-a151-71ad-e063-6394a90ac2da",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ketorolac tromethamine",
    "value": "20250505",
    "ingredients": [
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "KETOROLAC TROMETHAMINE",
            "code": "4EVE5946BQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6130"
        }
    ],
    "indications": {
        "text": "carefully consider potential benefits risks ketorolac tromethamine treatment options deciding ketorolac . lowest effective dose shortest duration consistent individual patient treatment goals ( ) . acute pain adult patients ketorolac tromethamine indicated short-term ( \u22645 days ) management moderately severe acute pain requires analgesia opioid level , usually postoperative setting . therapy always initiated intravenous intramuscular dosing ketorolac tromethamine , oral ketorolac tromethamine used continuation treatment , necessary . total combined duration ketorolac tromethamine injection oral ketorolac tromethamine exceed 5 days potential increasing frequency severity associated recommended doses ( , , , ) . patients switched alternative analgesics soon possible , ketorolac tromethamine therapy exceed 5 days .",
        "doid_entities": [
            {
                "text": "analgesia (DOID:0060145)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060145"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe acute pain",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_140896"
            }
        ]
    },
    "contraindications": {
        "text": "carefully consider potential benefits risks ketorolac tromethamine treatment options deciding ketorolac tromethamine . lowest effective dose shortest duration consistent individual patient treatment goals . adults , combined duration intravenous intramuscular dosing ketorolac tromethamine oral ketorolac tromethamine exceed 5 days . adults , oral ketorolac tromethamine indicated continuation therapy intravenous intramuscular dosing ketorolac tromethamine . package insert ketorolac tromethamine tablets transition intravenous intramuscular dosing ketorolac tromethamine ( single- multiple-dose ) multiple-dose oral ketorolac tromethamine . note : ral formulationshould notbe given initial dose . minimum effective dosefor individual patient . total duration treatment adult patients : combined duration intravenous intramuscular dosing ketorolac tromethamine oral ketorolac tromethamine exceed 5 days . ketorolac tromethamine injection ketorolac tromethamine injection may used single multiple dose regular \u201c needed \u201d schedule management moderately severe , acute pain requires analgesia opioid level , usually postoperative setting . hypovolemia corrected prior ketorolac tromethamine ( - renal effects ) . patients switched alternative analgesics soon possible , ketorolac tromethamine therapy exceed 5 days . administering ketorolac tromethamine injection , intravenous bolus must given less 15 seconds . intramuscular given slowly deeply muscle . analgesic effect begins ~30 minutes maximum effect 1 2 hours dosing intravenous intramuscular . duration analgesic effect usually 4 6 hours . single-dose treatment : following regimen limited single intramuscular dosing \u2022 patients < 65 years age : one dose 60 mg. \u2022 patients \u226565 years age , renally impaired and/or less 50 kg ( 110 lbs ) body weight : one dose 30 mg. intravenous dosing \u2022 patients < 65 years age : one dose 30 mg. \u2022patients \u226565 years age , renally impaired and/or less 50 kg ( 110 lbs ) body weight : one dose 15 mg. multiple-dose treatment ( intravenous intramuscular ) \u2022 patients < 65 years age : recommended dose 30 mg ketorolac tromethamine injection every 6 hours . maximum daily dose exceed 120 mg. \u2022 patients \u226565 years age , renally impaired patients ( ) , patients less 50 kg ( 110 lbs ) : recommended dose 15 mg ketorolac tromethamine injection every 6 hours . maximum daily dose exceed 60 mg. breakthrough pain , increase dose frequency ketorolac tromethamine . consideration given supplementing regimens low doses opioids `` needed `` unless otherwise contraindicated . pharmaceutical information ketorolac tromethamine injection ketorolac tromethamine injection mixed small volume ( e.g . , syringe ) morphine sulfate , meperidine hydrochloride , promethazine hydrochloride hydroxyzine hydrochloride ; result precipitation ketorolac solution . note : parenteral products inspected visually particulate matter discoloration prior , whenever solution container permit .",
        "doid_entities": [
            {
                "text": "analgesia (DOID:0060145)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060145"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "ketorolac tromethamine injection , usp supplied follows : ndc : 70518-3800-00 ndc : 70518-3800-01 packaging : 25 1 carton packaging : 2 ml 1 vial single dose , type 0 * im storage conditions store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature . ] protect light . retain carton time . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "( also boxed warning ) ketorolac tromethamine contraindicated patients previously demonstrated hypersensitivity ketorolac tromethamine . ketorolac tromethamine contraindicated patients active peptic ulcer disease , patients recent gastrointestinal bleeding perforation patients history peptic ulcer disease gastrointestinal bleeding . ketorolac tromethamine given patients experienced asthma , urticaria , allergic-type taking aspirin nsaids . severe , rarely fatal , anaphylactic-like nsaids reported patients ( \u2013 anaphylactoid , \u2013 pre-existing asthma ) . ketorolac tromethamine contraindicated prophylactic analgesic major surgery . ketorolac tromethamine contraindicated setting coronary artery bypass graft ( cabg ) surgery ( ) . ketorolac tromethamine contraindicated patients advanced renal impairment patients risk renal failure due volume depletion ( correction volume depletion ) . ketorolac tromethamine contraindicated labor delivery , prostaglandin synthesis inhibitory effect , may adversely affect fetal circulation inhibit uterine musculature , thus increasing risk uterine hemorrhage . ketorolac tromethamine inhibits platelet function , therefore , contraindicated patients suspected confirmed cerebrovascular bleeding , hemorrhagic diathesis , incomplete hemostasis high risk bleeding ( ) . ketorolac tromethamine contraindicated patients currently receiving aspirin nsaids cumulative risks inducing serious nsaid-related events . concomitant ketorolac tromethamine probenecid contraindicated . concomitant ketorolac tromethamine pentoxifylline contraindicated . ketorolac tromethamine injection contraindicated neuraxial ( epidural intrathecal ) due alcohol content .",
    "indications_original": "Carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see\n \n  WARNINGS).\u00a0 \n  \n                     \n                     Acute Pain in Adult Patients\n                     \n                       Ketorolac tromethamine is indicated for the short-term (\u22645 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with intravenous or intramuscular dosing\u00a0of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. \n  \n                       The total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see\n \n  \n                        WARNINGS,\n  \n   PRECAUTIONS,\n  \n   DOSAGE AND ADMINISTRATION\n                     , and\n \n  \n                        ADVERSE REACTIONS\n                     ). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days.",
    "contraindications_original": "Carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac tromethamine. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. In adults, the combined duration of use of intravenous or intramuscular dosing of ketorolac tromethamine and oral ketorolac tromethamine is not to exceed 5 days. In adults, the use of oral ketorolac tromethamine is only indicated as continuation therapy to intravenous or intramuscular dosing of ketorolac tromethamine. See package insert for ketorolac tromethamine tablets for transition from intravenous or intramuscular dosing of ketorolac tromethamine (single- or multiple-dose) to multiple-dose oral ketorolac tromethamine.\n                     \n                     \n                     Note: O\n                     ral formulationshould\n \n  notbe given\n \n  as an initial dose.\n                  \n                  \n                  \n                     Use minimum effective dosefor the individual patient.\n\n \n                  \n                     Total duration of treatment in adult patients:the combined duration of use of intravenous or intramuscular dosing of ketorolac tromethamine and oral ketorolac tromethamine is not to exceed 5 days.\n\n \n                  \n                  \n                  \n                     KETOROLAC TROMETHAMINE INJECTION\n                  \n                  \n                  \n                  \n                     \n                  \n                  \n                  Ketorolac tromethamine injection may be used as a single or multiple dose on a regular or \u201cas needed\u201d schedule for the management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Hypovolemia should be corrected prior to the administration of ketorolac tromethamine (see\n \n  \n                        WARNINGS - Renal Effects\n                     ). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days. \n  \n                       When administering ketorolac tromethamine injection, the intravenous bolus must be given over no less than 15 seconds. The intramuscular administration should be given slowly and deeply into the muscle. The analgesic effect begins in ~30 minutes with maximum effect in 1 to 2 hours after dosing intravenous or intramuscular. Duration of analgesic effect is usually 4 to 6 hours. \n  \n                     \n                     Single-Dose Treatment: The following regimen should be limited to single administration use only\n                     \n                     Intramuscular Dosing\n                       \u2022 Patients <65 years of age: One dose of 60 mg. \n    \u2022 Patients \u226565 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight:\n\n \n                  \n                  \n                  One dose of 30 mg. \n  \n                     \n                     Intravenous Dosing\n                       \u2022 Patients <65 years of age: One dose of 30 mg. \n  \n                     \u2022Patients \u226565 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight:One dose of 15 mg. \n  \n                     \n                     Multiple-Dose Treatment (Intravenous or Intramuscular)\n                       \u2022 Patients <65 years of age: The recommended dose is 30 mg ketorolac tromethamine injection every 6 hours. The maximum daily dose for these populations should \n    not exceed 120 mg. \n    \u2022 For patients \u226565 years of age, renally impaired patients (see\n \n  \n                        WARNINGS\n                     ), and patients less than 50 kg (110 lbs): The recommended dose is 15 mg ketorolac tromethamine injection every 6 hours. The maximum daily dose for these populations should not exceed 60 mg.\n\n \n                  \n                  \n                  For breakthrough pain, do not increase the dose or the frequency of ketorolac tromethamine. Consideration should be given to supplementing these regimens with low doses of opioids \"as needed\" unless otherwise contraindicated. \n  \n                     Pharmaceutical Information for Ketorolac Tromethamine Injection\n                  \n                  \n                  \n                  Ketorolac tromethamine injection should not be mixed in a small volume (e.g., in a syringe) with morphine sulfate, meperidine hydrochloride, promethazine hydrochloride or hydroxyzine hydrochloride; this will result in precipitation of ketorolac from solution.\n                  \n                  \n                     NOTE:Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.",
    "warningsAndPrecautions_original": "Ketorolac Tromethamine Injection, USP is supplied as follows:\n                  \n                  NDC: 70518-3800-00\n                  NDC: 70518-3800-01\n                  PACKAGING: 25 in 1 CARTON\n                  PACKAGING: 2 mL in 1 VIAL SINGLE DOSE, TYPE 0\n                  \n                  *FOR IM USE ONLY\n                  Storage Conditions\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.]\n                  Protect from light. Retain in carton until time of use.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "(see also\n \n  \n                        Boxed WARNING)\n \n  \n                       Ketorolac tromethamine is contraindicated in patients with previously demonstrated hypersensitivity to ketorolac tromethamine. \n    Ketorolac tromethamine is contraindicated in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. \n  \n                       Ketorolac tromethamine should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see\n \n  \n                        WARNINGS\n                     \n                  \n                  \n                     \u2013\u00a0\n                     Anaphylactoid Reactions, and\n \n  \n                        PRECAUTIONS\u00a0\u2013\u00a0Pre-existing Asthma\n                     ).\n\n \n                  \n                  \n                  Ketorolac tromethamine is contraindicated as prophylactic analgesic before any major surgery. \n  \n                       Ketorolac tromethamine is contraindicated\u00a0in the setting of coronary artery bypass graft (CABG) surgery (see\n \n  \n                        WARNINGS\n                     ). \n  \n                       Ketorolac tromethamine is contraindicated in patients with advanced renal impairment or in patients at risk for renal failure due to volume depletion (see\n \n  \n                        WARNINGS\n                     for correction of volume depletion). \n  \n                       Ketorolac tromethamine is contraindicated in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine musculature, thus increasing the risk of uterine hemorrhage. \n  \n                       Ketorolac tromethamine inhibits platelet function and is, therefore, contraindicated in patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis and those at high risk of bleeding (see\n \n  \n                        WARNINGS\n                     and\n \n  \n                        PRECAUTIONS\n                     ). \n  \n                       Ketorolac tromethamine is contraindicated in patients currently receiving aspirin or NSAIDs because of the cumulative risks of inducing serious NSAID-related adverse events. \n  \n                       The concomitant use of ketorolac tromethamine and probenecid is contraindicated. \n  \n                       The concomitant use of ketorolac tromethamine and pentoxifylline is contraindicated. \n    \u00a0Ketorolac tromethamine injection is contraindicated for neuraxial (epidural or intrathecal) administration due to its alcohol content.",
    "drug": [
        {
            "name": "ketorolac tromethamine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6130"
        }
    ]
}